Xingyi Shi

584 total citations
6 papers, 122 citations indexed

About

Xingyi Shi is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xingyi Shi has authored 6 papers receiving a total of 122 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Cancer Research and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xingyi Shi's work include Renal and related cancers (2 papers), Cancer-related molecular mechanisms research (2 papers) and MicroRNA in disease regulation (2 papers). Xingyi Shi is often cited by papers focused on Renal and related cancers (2 papers), Cancer-related molecular mechanisms research (2 papers) and MicroRNA in disease regulation (2 papers). Xingyi Shi collaborates with scholars based in United States, Poland and Taiwan. Xingyi Shi's co-authors include Subhayan Sur, Robert Steele, Ratna B. Ray, Florin L. Craciun, Diana Rubel, Hervé Husson, Shiguang Liu, Nicholas Ngai, William Weber and Oxana Ibraghimov‐Beskrovnaya and has published in prestigious journals such as The FASEB Journal, Cells and Frontiers in Cardiovascular Medicine.

In The Last Decade

Xingyi Shi

6 papers receiving 120 citations

Peers

Xingyi Shi

MB

CR

PRM

ONCOL

GENET

Mojca Adlesic Switzerland

Kahira L. Saez‐Torres United States

Yuanqiang Dong China

P. Gajate Borau Spain

Tom Hofste Netherlands

Lingzhi Xu China

José Ignacio Arias Pérez Spain

Alberto Tenorio‐Torres Mexico

Cornelius Pauli Germany

Fangchao Gong China

Mojca Adlesic Switzerland

Xingyi Shi

74 ×0.8

MB

40 ×0.6

CR

36 ×1.8

PRM

9 ×0.9

ONCOL

12 ×1.3

GENET

Citations per year, relative to Xingyi Shi Xingyi Shi (= 1×) peers Mojca Adlesic

Countries citing papers authored by Xingyi Shi

Since Specialization

Citations

This map shows the geographic impact of Xingyi Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xingyi Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xingyi Shi more than expected).

Fields of papers citing papers by Xingyi Shi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xingyi Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xingyi Shi. The network helps show where Xingyi Shi may publish in the future.

Co-authorship network of co-authors of Xingyi Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Xingyi Shi. A scholar is included among the top collaborators of Xingyi Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xingyi Shi. Xingyi Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Cuppens, Kristof, K. Papadopoulos, Makoto Nishio, et al.. (2025). 8O First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4). ESMO Open. 10. 104164–104164. 1 indexed citations

2.

Rubel, Diana, Joseph Boulanger, Florin L. Craciun, et al.. (2022). Anti-microRNA-21 Therapy on Top of ACE Inhibition Delays Renal Failure in Alport Syndrome Mouse Models. Cells. 11(4). 594–594. 27 indexed citations

3.

Burks, Eric, Jiarui Zhang, Travis Sullivan, et al.. (2021). Pathologic and gene expression comparison of CT- screen detected and routinely detected stage I/0 lung adenocarcinoma in NCCN risk-matched cohorts.. Cancer Treatment and Research Communications. 29. 100486–100486. 4 indexed citations

4.

Zhao, Yuqi, Montgomery Blencowe, Xingyi Shi, et al.. (2019). Integrative Genomics Analysis Unravels Tissue-Specific Pathways, Networks, and Key Regulators of Blood Pressure Regulation. Frontiers in Cardiovascular Medicine. 6. 21–21. 12 indexed citations

5.

Sur, Subhayan, Robert Steele, Xingyi Shi, & Ratna B. Ray. (2019). miRNA-29b Inhibits Prostate Tumor Growth and Induces Apoptosis by Increasing Bim Expression. Cells. 8(11). 1455–1455. 77 indexed citations

6.

Shi, Xingyi & Lina I. Yoo. (2018). Investigation of PKHD1L1's Localization and Potential Function as a Tumor Suppressor. The FASEB Journal. 32(S1). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact